Hyperfine Interactions

, Volume 189, Issue 1–3, pp 31–37

Iron in the brain

  • Jolanta Galazka-Friedman
  • Andrzej Friedman
  • Erika R. Bauminger


The results of our studies of iron in three brain structures, substantia nigra (SN), globus pallidus (GP), and hippocampus (Hip), are presented. Mössbauer spectroscopy, electron microscopy and ELISA (enzyme-linked immuno-absorbent assay) were applied. Mössbauer studies show that most of the iron in the brain is ferritin-like. The concentration of iron is similar in SN and GP, but less than half of this in Hip. ELISA studies showed that the H/L ratio of ferritin in SN and GP is also similar, but is about three times higher in Hip. These results suggest that the role of iron in SN and GP may be different from that in Hip. Electron microscopy shows that the diameters of the ferritin iron cores in the brain are smaller that in the liver (3.5 ± 0.5 nm vs. 6.0 ± 0.5 nm). Mössbauer studies yield the ratio between the concentration of iron in control and parkinsonian SN as 1.00 ± 0.13.


Human brain iron Mössbauer spectroscopy Electron microscopy ELISA Parkinson’s disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hallgren, B., Sourander, P.: The effect of age on the non-haemin iron the human brain. J. Neurochem. 3, 41–51 (1958)CrossRefGoogle Scholar
  2. 2.
    Martin, W.R., Ye, F.Q., Allen, P.S.: Increasing striatal iron content associated with normal aging. Mov. Disord. 13, 281–286 (1998)CrossRefGoogle Scholar
  3. 3.
    Gałązka-Friedman, J., Friedman, A.: Controversies about iron in parkinsonian and control substantia nigra. Acta Neurobiol. Exp. 57, 210–225 (1997)Google Scholar
  4. 4.
    Bauminger, E.R., Barcikowska, M., Friedman, A., Gałązka-Friedman, J., Hechel, D., Nowik, I.: Does iron play a role in Parkinson’s disease? Hyperfine Interact. 91, 853–856 (1994)CrossRefADSGoogle Scholar
  5. 5.
    Gałązka-Friedman, J., Bauminger, E.R., Friedman, A., Barcikowska, M., Hechel, D., Nowik, I.: Iron in parkinsonian and control substantia nigra—a Mössbauer spectroscopy study. Mov. Disord. 11, 8–16 (1996)CrossRefGoogle Scholar
  6. 6.
    Gałązka-Friedman, J., Bauminger, E.R., Tymosz, T., Friedman, A.: Mössbauer spectroscopy, electron microscopy and electron diffraction studies of ferritin-like iron in human heart, liver and brain. Hyperfine Interact. (C)3, 49–52 (1998)Google Scholar
  7. 7.
    Friedman, A., Gałązka-Friedman, J.: The current state of free radicals in Parkinson’s disease. Nigral iron as a trigger of oxidative stress. Adv. Neurol. 86, 137–142 (2001)Google Scholar
  8. 8.
    Galazka-Friedman, J., Bauminger, E.R., Friedman, A.: Iron in Parkinson’s disease—revisited. Hyperfine Interact. 141/142, 267–271 (2002)CrossRefADSGoogle Scholar
  9. 9.
    Galazka-Friedman, J., Bauminger, E.R., Koziorowski, D., Friedman, A.: Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson’s disease and control substantia nigra. Biochim. Biophys. Acta 1688, 130–136 (2004)Google Scholar
  10. 10.
    Galazka-Friedman, J., Bauminger, E.R., Friedman, A., Koziorowski, D., Szlachta, K.: Human nigral and liver iron—comparison by Mössbauer spectroscopy, electron microscopy and ELISA. Hyperfine Interact. 165, 285–288 (2005)CrossRefADSGoogle Scholar
  11. 11.
    Gerlach, M., Trautwein, A.X., Zecca, L., Youdim, M.B.H., Riederer, P.: Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J. Neurochem. 65, 923–926 (1995)CrossRefGoogle Scholar
  12. 12.
    Zecca, L., Gallorini, M., Schuenemann, V., Trautwein, A.X., Gerlach, M., Riederer, P., Vezzoni, P., Tampellini, D.: Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76, 1766–1773 (2001)CrossRefGoogle Scholar
  13. 13.
    Double, K.L., Gerlach, M., Schuenemann, V., Trautwein, A.X., Zecca, L., Gallorini, M., Youdim, M.B.H., Riederer, P., Ben-Shachar, D.: Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol. 66, 489–494 (2003)CrossRefGoogle Scholar
  14. 14.
    Dubiel, S.M., Zablotna-Rypien, B., Mackey, J.B., Williams, J.M.: Magnetic properties of human liver and brain ferritin. Eur. Biophys. J. 28, 263–267 (1999)CrossRefGoogle Scholar
  15. 15.
    Harrison, P.M., Arosio, P.: The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta 1275, 161–203 (1996)CrossRefGoogle Scholar
  16. 16.
    Williams, J.M., Andrew, S.C., Treffry, A., Harrison, P.M.: The relationship between ferritin and haemosiderin. Hyperfine Interact. 29, 1447–1450 (1986)CrossRefADSGoogle Scholar
  17. 17.
    Bell, S.H., Weir, M.P., Dickson, D.P., Gibson, J.F., Sharp, G.A., Peters, T.J.: Mössbauer spectroscopic studies of human haemosiderin and ferritin. Biochim. Biophys. Acta 787, 227–236 (1984)Google Scholar
  18. 18.
    Braak, H., Braak, E.: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. (Berl) 82, 239–259 (1991)CrossRefGoogle Scholar
  19. 19.
    Jellinger, K., Kienzel, E., Rumpelmair, G., Riederer, P., Stachelberger, H., Ben-Shachar, D., Youdim, M.B.H.: Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J. Neurochem. 59, 1168–1171 (1992)CrossRefGoogle Scholar
  20. 20.
    Zecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., Giaveri, G., Arosio, P., Santambrogio, P., Fariello, R.G., Karatekin, E., Kleinman, M.H., Torro, N., Hornykiewicz, O., Zucca, F.A.: The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl. Acad. Sci. U. S. A. 101, 9843–9848 (2004)CrossRefADSGoogle Scholar
  21. 21.
    Friedman, A., Galazka-Friedman, J., Bauminger, E.R.: Iron as a trigger of neurodegeneration in Parkinson’s disease. In: Koller, W., Melamed, E. (eds.) Handbook of Clinical Neurology, Parkinson’s Disease and Related Disorders, vol. 83, pp. 493–506, ISBN 0444519009. Elsevier (2007)Google Scholar
  22. 22.
    Galazka-Friedman, J., Bauminger, E.R., Szlachta, K., Wszolek, Z., Dickson, D., Friedman, A.: Is the substantial increase of iron concentration in parkinsonian substantia nigra a real fact? XLII Zakopane School of Physics International Symposium. Zakopane 2008, Book of abstracts, p. 28 (2008)Google Scholar
  23. 23.
    Zhu, W., Xie, W., Pan, T., Xu, P., Fridkin, M., Zheng, H., Jankovic, J., Youdim, M.B.H., Le, W.: Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 21, 3835–3844 (2007)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Jolanta Galazka-Friedman
    • 1
  • Andrzej Friedman
    • 2
  • Erika R. Bauminger
    • 3
  1. 1.Faculty of PhysicsWarsaw University of TechnologyWarsawPoland
  2. 2.Department of NeurologyMedical University of WarsawWarsawPoland
  3. 3.Racah Institute of PhysicsThe Hebrew UniversityJerusalemIsrael

Personalised recommendations